Search results for "vaccines"

showing 10 items of 554 documents

Langerhans cells are negative regulators of the anti-Leishmania response

2011

Langerhans cells suppress the immune response to low-dose Leishmania major infection in part by inducing regulatory T cells.

LangerinT cellImmunologyPriming (immunology)Leishmaniasis Cutaneouschemical and pharmacologic phenomenaT-Lymphocytes RegulatoryImmune toleranceInterferon-gammaMiceImmune systemSDG 3 - Good Health and Well-beingparasitic diseasesmedicineImmune ToleranceImmunology and AllergyAnimalsInterferon gammaLeishmania majorLeishmaniasis VaccinesLeishmania majorbiologyintegumentary systemBrief Definitive ReportFOXP3hemic and immune systemsbiochemical phenomena metabolism and nutritionTh1 Cellsbiology.organism_classificationDisease Models Animalmedicine.anatomical_structureLangerhans CellsImmunologybiology.proteinmedicine.drug
researchProduct

Chapter 14: HPV vaccine introduction in industrialized countries.

2006

Introduction of a vaccine requires the achievement of three initial milestones. These are licensure by a national control authority that determines the vaccine is safe and effective, development of recommendations for use by expert advisory bodies on immunization, and obtaining funding for vaccination. Once these milestones have been achieved, a successful vaccination program requires that a number of interlinked programmatic components be brought together in a coordinated fashion. These include vaccine purchase and supply, vaccination service delivery, high coverage rates, surveillance of the vaccination program, immunization finance policies and practices, and political will. Human papill…

LicensureEconomic growthGeneral VeterinaryGeneral Immunology and MicrobiologyService delivery frameworkbusiness.industryDeveloped CountriesPapillomavirus InfectionsPublic Health Environmental and Occupational HealthImmunization (finance)High coverageVaccine introductionVaccinationInfectious DiseasesImmunologyMolecular MedicineMedicineHumansFemalePapillomavirus VaccinesHuman papillomavirusbusinessDeveloped countryHealth Services AdministrationVaccine
researchProduct

Chapter 22: Assuring the quality, safety and efficacy of HPV vaccines: The scientific basis of regulatory expectations pre- and post-licensure

2006

The potential of human papillomavirus (HPV) vaccines will only be realized if the vaccine candidates under development prove to be safe and effective and can be consistently produced to define quality standards. Whilst the responsibility for delivering a safe and effective product rests with the vaccine producer, a vaccine requires a license to allow it to be placed on the market. Licensure is based on an evaluation of the safety and efficacy profile of a vaccine candidate by national regulatory authorities, ideally on the basis of internationally agreed, science-based specifications and procedures. For vaccines, these international specifications are developed by the World Health Organizat…

LicensureGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industrymedia_common.quotation_subjectPublic Health Environmental and Occupational HealthMEDLINEHPV vaccinesPublic relationsProduct (business)Infectious DiseasesQuality safetyHumansMolecular MedicineMedicineQuality (business)Papillomavirus VaccinesbusinessLicensureLicenseDisease burdenmedia_commonVaccine
researchProduct

SARS-CoV-2 infection in patients with a normal or abnormal liver.

2020

Abstract Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), a novel coronavirus causing coronavirus disease 19 (COVID‐19), with an estimated 22 million people infected worldwide so far although involving primarily the respiratory tract, has a remarkable tropism for the liver and the biliary tract. Patients with SARS‐CoV‐2 infection and no antecedent liver disease may display evidence of cytolytic liver damage, proportional to the severity of COVID‐19 but rarely of clinical significance. The mechanism of hepatocellular injury is unclear and possibly multifactorial. The clinical impact of SARS‐CoV‐2 infection in patients with underlying chronic liver disease, a cohort whose global …

Liver CirrhosisRiskmedicine.medical_specialtyCirrhosisCOVID-19 VaccinesCOVID-19 VaccineLiver CirrhosiPopulationDiseaseChronic liver diseasemedicine.disease_causeSARS‐CoV‐2Liver diseaseCOVID‐19VirologyInternal medicinevaccinemedicineHumansClinical significanceeducationCoronaviruseducation.field_of_studySettore MED/12 - GastroenterologiaHepatologybusiness.industryTransmission (medicine)SARS-CoV-2Liver DiseasescirrhosisCOVID-19chronic liver diseaseprioritizationmedicine.diseaseInfectious DiseasesLiverNon‐commissioned ReviewChronic DiseasebusinesscirrhosiHumanJournal of viral hepatitis
researchProduct

Prevalence of unwillingness and uncertainty to vaccinate against COVID-19 in older people: A systematic review and meta-analysis.

2021

The coronavirus disease 2019 (COVID-19) has been shown to have more severe health outcomes in older people specifically in relation to mortality and disability. Vaccination seems to be efficacious and safe for preventing the negative consequences of COVID-19, but vaccine hesitancy seems to be high in older adults. We therefore aimed to investigate the prevalence of unwillingness and the uncertainty to vaccinate against COVID-19 in older people and the factors that can be associated with the unwillingness to vaccinate. For this work, we searched several databases until 18th June 2021 for studies reporting the prevalence of unwillingness and the uncertainty to vaccinate against COVID-19 in pe…

Low incomeAgingCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)ReviewHealth outcomesBiochemistryolder adultvaccinePrevalenceMedicineHumansMolecular Biologyolder adultsAgedbusiness.industrySARS-CoV-2VaccinationUncertaintyCOVID-19Odds ratioConfidence intervalVaccinationCross-Sectional StudiesNeurologyMeta-analysisCOVID-19; hesitancy; older adults; vaccine; Aged; Cross-Sectional Studies; Humans; Prevalence; SARS-CoV-2; Uncertainty; Vaccination; COVID-19; COVID-19 VaccineshesitancyOlder peoplebusinessBiotechnologyDemographyAgeing research reviews
researchProduct

[Vaccination against papillomavirus : arguments and evidence of effectiveness].

2020

Vaccination against papillomavirus: arguments and evidence of effectiveness. Vaccination against human papillomavirus is a major advance in the prevention of cervical cancer. Evidence of its effectiveness has accumulated over the past thirty years since basic research has demonstrated the ability of viral pseudoparticles to induce immune responses in animals. Large human clinical trials followed to demonstrate the safety and efficacy of vaccination against targeted HPV infections and their associated lesions. After its approval and marketing the vaccine efficacy was measured at the level of entire populations, confirming its effectiveness and medical interest. Today, models predict a possib…

MESH: HumansPapillomavirus InfectionsVaccinationUterine Cervical Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerMESH: Papillomavirus VaccinesMESH: VaccinationMESH: Papillomavirus InfectionsMESH: Uterine Cervical Neoplasms[SDV.CAN] Life Sciences [q-bio]/CancerHumansFemalePapillomavirus VaccinesDisease EradicationMESH: FemaleLa Revue du praticien
researchProduct

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

2016

Lymphoid organs, in which antigen presenting cells (APCs) are in close proximity to T cells, are the ideal microenvironment for efficient priming and amplification of T-cell responses. However, the systemic delivery of vaccine antigens into dendritic cells (DCs) is hampered by various technical challenges. Here we show that DCs can be targeted precisely and effectively in vivo using intravenously administered RNA-lipoplexes (RNA-LPX) based on well-known lipid carriers by optimally adjusting net charge, without the need for functionalization of particles with molecular ligands. The LPX protects RNA from extracellular ribonucleases and mediates its efficient uptake and expression of the encod…

Male0301 basic medicineLymphoid TissueT-Lymphocytesmedicine.medical_treatmentStatic ElectricityPriming (immunology)BiologyLymphocyte ActivationAutoantigensCancer VaccinesMice03 medical and health sciences0302 clinical medicineAntigenCancer immunotherapyAntigens NeoplasmInterferonmedicineAnimalsHumansAntigen-presenting cellAntigens ViralMelanomaAntigen PresentationDrug CarriersMembrane GlycoproteinsMultidisciplinaryInnate immune systemClinical Trials Phase I as TopicEffectorMacrophagesRNADendritic CellsMice Inbred C57BLDisease Models Animal030104 developmental biologyToll-Like Receptor 7030220 oncology & carcinogenesisInterferon Type IImmunologyCancer researchNanoparticlesRNAAdministration IntravenousFemaleImmunotherapymedicine.drugNature
researchProduct

Mandatory vaccinations in European countries, undocumented information, false news and the impact on vaccination uptake: the position of the Italian …

2018

Abstract Background High rates of vaccination coverage are important in preventing infectious diseases. Enforcing mandatory vaccinations is one of the strategies that some Countries adopted to protect the community when vaccination coverage is not satisfactory. In Italy, in 2017 vaccination against diphtheria, tetanus, pertussis, hepatitis B, poliovirus, Haemophilus influenzae type b, measles, mumps, rubella and varicella became compulsory in childhood. In order to contrast vaccination policies, anti-vaccination campaigns contribute to the spread of fake news. Among them, there is the false information that Italy is the only one country with mandatory vaccination policy. Aim of our study is…

Male0301 basic medicineVaricella vaccine030106 microbiologyMandatory ProgramsWorld Health OrganizationPediatricscomplex mixturesMeaslesRubellaTreatment RefusalVaccination policies03 medical and health sciences0302 clinical medicineEnvironmental healthmedicineHumans030212 general & internal medicinePolicy MakingChildrenSocieties MedicalTetanusbusiness.industryResearchHealth PolicyDiphtheriaVaccinationlcsh:RJ1-570Infantvirus diseasesViral Vaccineslcsh:Pediatricsmedicine.diseaseSettore MED/38PoliomyelitisEuropeVaccinationItalyImmunizationChild PreschoolBacterial VaccinesCommunicable Disease ControlPatient ComplianceFemalebusinessItalian Journal of Pediatrics
researchProduct

Trends of influenza B during the 2010–2016 seasons in 2 regions of north and south Italy: The impact of the vaccine mismatch on influenza immunisatio…

2017

Influenza A and B viruses are responsible for respiratory infections, representing globally seasonal threats to human health. The 2 viral types often co-circulate and influenza B plays an important role in the spread of infection. A 6-year retrospective surveillance study was conducted between 2010 and 2016 in 2 large administrative regions of Italy, located in the north (Liguria) and in the south (Sicily) of the country, to describe the burden and epidemiology of both B/Victoria and B/Yamagata lineages in different healthcare settings. Influenza B viruses were detected in 5 of 6 seasonal outbreaks, exceeding influenza A during the season 2012–2013. Most of influenza B infections were found…

Male0301 basic medicinevirusesInfluenza B viruDisease OutbreaksHuman health0302 clinical medicineRetrospective StudieEpidemiologyImmunology and Allergy030212 general & internal medicinehospitalChildSicilyB/Victoriaeducation.field_of_studyDisease OutbreakVaccinationvirus diseasesB/Victoria; B/Yamagata; community; hospital; Influenza type B; lineage; vaccine-mismatch; Immunology and Allergy; Immunology; Pharmacologyvaccine-mismatchInfluenza type BInfluenza A viruInfluenza A virusInfluenza VaccinesChild PreschoolcommunityCommunity settingFemaleSeasonsInfluenza VaccineHumanResearch Papermedicine.medical_specialty030106 microbiologyImmunologyPopulationEpidemic03 medical and health sciencesInfluenza HumanmedicineHumansEpidemicseducationRetrospective StudiesPharmacologyInfluenza immunisationbusiness.industryOutbreakInfluenza aVirologyInfluenza B virusVaccine mismatchSeasonbusinessB/YamagatalineageDemographyHuman Vaccines & Immunotherapeutics
researchProduct

Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment…

2018

Vacunación; Narcolepsia; Simulación y modelado: en Vacunació; Narcolèpsia; Simulació i modelització Vaccination; Narcolepsy; Simulation and modeling Background & objectives Vaccine safety signals require investigation, which may be done rapidly at the population level using ecological studies, before embarking on hypothesis-testing studies. Incidence rates were used to assess a signal of narcolepsy following AS03-adjuvanted monovalent pandemic H1N1 (pH1N1) influenza vaccination among children and adolescents in Sweden and Finland in 2010. We explored the utility of ecological data to assess incidence of narcolepsy following exposure to pandemic H1N1 virus or vaccination in 10 sites that use…

Male:Other subheadings::Other subheadings::/epidemiology [Other subheadings]medicine.medical_treatmentlcsh:Medicine:Other subheadings::Other subheadings::/drug therapy [Other subheadings]medicine.disease_causeGeographical locations:enfermedades del sistema nervioso::trastornos del sueño-vigilia::disomnias::trastornos intrínsecos del sueño::trastornos de somnolencia excesiva::narcolepsia [NarcolepsiaENFERMEDADES]Influenza A Virus H1N1 Subtype0302 clinical medicineRisk FactorsPandemicMedicine and Health SciencesInfluenza A virusMedicinePublic and Occupational Health030212 general & internal medicineYoung adultChildlcsh:Science:Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores]Aged 80 and overVaccinesMultidisciplinaryIncidenceSimulation and ModelingIncidence (epidemiology)Vaccination:Otros calificadores::Otros calificadores::/epidemiología [Otros calificadores]Middle AgedVaccination and ImmunizationEuropeVaccinationInfectious DiseasesNeurologyInfluenza VaccinesChild PreschoolsymbolsEngineering and TechnologyFemaleSafetyNarcolèpsia - TractamentAdjuvantResearch ArticleAdultCanadaAsiaAdolescentInfectious Disease ControlImmunologyTaiwanResearch and Analysis MethodsYoung Adult03 medical and health sciencessymbols.namesakeAdjuvants ImmunologicEnvironmental healthInfluenza HumanHumansComputer SimulationEuropean UnionPoisson regressionAgedTrastorns del sonNarcolepsySwedenModels Statisticalbusiness.industrylcsh:RInfant NewbornNarcolèpsia - EpidemiologiaInfantBiology and Life SciencesDyssomniasAge GroupsR - MedicineRelative riskSignal ProcessingPopulation Groupingslcsh:QPreventive MedicinePeople and placesSleep Disordersbusiness030217 neurology & neurosurgeryPLOS ONE
researchProduct